Objective: Previous studies on the association between tea consumption and bladder cancer risk have only illustrated contradictory results. The role of tea in bladder carcinogenesis still remains conflicting. In order to illustrate the potential relationship between tea consumption and bladder cancer, a meta-analysis of case-control and cohort studies was conducted. Methods: Eligible studies were retrieved via both computerized searches and review of references. Stratified analyses on types of tea, gender, study design, ethnicity and smoking status were performed. Fixed- or random-effect models were used to summarize the estimates of OR with 95% CIs. Results: Seventeen studies were eligible for our analysis. No statistical significance was detected between tea consumption and bladder cancer risk when comparing the highest with the lowest intake of tea (OR = 0.825, 95% CI 0.652–1.043). In the subgroup of green tea, we observed it illustrated a protective effect on bladder cancer (OR = 0.814, 95% CI 0.678–0.976). Conclusion: Our analysis indicated that green tea may have a protective effect on bladder cancer in Asian people. Further studies need to be conducted to better clarify the biological mechanisms.

Keywords:
Etiology, Meta-analysis, Bladder cancer, Tea consumption
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
2.
Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 2012;62:10–29.
3.
Kiemeney LA, Schoenberg M: Familial transitional cell carcinoma. J Urol 1996;156:867–872.
4.
Czene K, Lichtenstein P, Hemminki K: Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish Family-Cancer Database. Int J Cancer 2002;99:260–266.
5.
Lynch CF, Cohen MB: Urinary system. Cancer 1995;75(1 suppl):316–329.
6.
Brennan P, Bogillot O, Cordier S, et al: Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer 2000;86:289–294.
7.
Vineis P, Simonato L: Proportion of lung and bladder cancers in males resulting from occupation: a systematic approach. Arch Environ Health 1991;46:6–15.
8.
Qin J, Xie LP, Zheng XY, Wang YB, Bai Y, Shen HF, Li LC, Dahiya R: A component of green tea, (–)-epigallocatechin-3-gallate, promotes apoptosis in T24 human bladder cancer cells via modulation of the PI3K/Akt pathway and Bcl-2 family proteins. Biochem Biophys Res Commun 2007;354:852–857.
9.
Adhami VM, Ahmad N, Mukhtar H: Molecular targets for green tea in prostate cancer prevention. J Nutr 2003;133(7 suppl):2417S–2424S.
10.
Sartippour MR, Heber D, Ma J, Lu Q, Go VL, Nguyen M: Green tea and its catechins inhibit breast cancer xenografts. Nutr Cancer 2001;40:149–156.
11.
Wakai K, Hirose K, Takezaki T, Hamajima N, Ogura Y, Nakamura S, Hayashi N, Tajima K: Foods and beverages in relation to urothelial cancer: case-control study in Japan. Int J Urol 2004;11:11–19.
12.
Lu CM, Lan SJ, Lee YH, Huang JK, Huang CH, Hsieh CC: Tea consumption: fluid intake and bladder cancer risk in Southern Taiwan. Urology 1999;54:823–828.
13.
De Stefani E, Boffetta P, Deneo-Pellegrini H, Correa P, Ronco AL, Brennan P, Ferro G, Acosta G, Mendilaharsu M: Non-alcoholic beverages and risk of bladder cancer in Uruguay. BMC Cancer 2007;7:57.
14.
Hemelt M, Hu Z, Zhong Z, et al: Fluid intake and the risk of bladder cancer: results from the South and East China case-control study on bladder cancer. Int J Cancer 2010;127:638–645.
15.
Zeegers MP, Tan FE, Goldbohm RA, van den Brandt PA: Are coffee and tea consumption associated with urinary tract cancer risk? A systematic review and meta-analysis. Int J Epidemiol 2001;30:353–362.
16.
Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719–748.
17.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–188.
18.
Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003;327:557–560.
19.
Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–634.
20.
Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–1101.
21.
Nagano J, Kono S, Preston DL, Mabuchi K: A prospective study of green tea consumption and cancer incidence, Hiroshima and Nagasaki (Japan). Cancer Causes Control 2001;12:501–508.
22.
Zeegers MP, Dorant E, Goldbohm RA, van den Brandt PA: Are coffee, tea, and total fluid consumption associated with bladder cancer risk? Results from the Netherlands Cohort Study. Cancer Causes Control 2001;12:231–238.
23.
Heilbrun LK, Nomura A, Stemmermann GN: Black tea consumption and cancer risk: a prospective study. Br J Cancer 1986;54:677–683.
24.
Ohno Y, Aoki K, Obata K, Morrison AS: Case-control study of urinary bladder cancer in metropolitan Nagoya. Natl Cancer Inst Monogr 1985;69:229–234.
25.
Woolcott CG, King WD, Marrett LD: Coffee and tea consumption and cancers of the bladder, colon and rectum. Eur J Cancer Prev 2002;11:137–145.
26.
Kurahashi N, Inoue M, Iwasaki M, Sasazuki S, Tsugane S: Coffee, green tea, and caffeine consumption and subsequent risk of bladder cancer in relation to smoking status: a prospective study in Japan. Cancer Sci 2009;100:284–291.
27.
Slattery ML, West DW, Robison LM: Fluid intake and bladder cancer in Utah. Int J Cancer 1988;42:17–22.
28.
Bruemmer B, White E, Vaughan TL, Cheney CL: Fluid intake and the incidence of bladder cancer among middle-aged men and women in a three-county area of western Washington. Nutr Cancer 1997;29:163–168.
29.
Kunze E, Chang-Claude J, Frentzel-Beyme R: Life style and occupational risk factors for bladder cancer in Germany. A case-control study. Cancer 1992;69:1776–1790.
30.
La Vecchia C, Negri E, Franceschi S, D’Avanzo B, Boyle P: Tea consumption and cancer risk. Nutr Cancer 1992;17:27–31.
31.
Bianchi GD, Cerhan JR, Parker AS, Putnam SD, See WA, Lynch CF, Cantor KP: Tea consumption and risk of bladder and kidney cancers in a population-based case-control study. Am J Epidemiol 2000;151:377–383.
32.
Jensen OM, Wahrendorf J, Knudsen JB, Sorensen BL: The Copenhagen case-control study of bladder cancer. II. Effect of coffee and other beverages. Int J Cancer 1986;37:651–657.
33.
Jiang X, Castelao JE, Groshen S, Cortessis VK, Shibata DK, Conti DV, Gago-Dominguez M: Water intake and bladder cancer risk in Los Angeles County. Int J Cancer 2008;123:1649–1656.
34.
Nagano J, Kono S, Preston DL, Moriwaki H, Sharp GB, Koyama K, Mabuchi K: Bladder-cancer incidence in relation to vegetable and fruit consumption: a prospective study of atomic-bomb survivors. Int J Cancer 2000;86:132–138.
35.
Gumus B, Aras O, Atesci YZ, Muezzinoglu T: Aetiological factors of bladder cancer in the Aegean region of Turkey between the years 1985–1996. Int Urol Nephrol 1999;31:197–202.
36.
Yu Y, Hu J, Wang PP, Zou Y, Qi Y, Zhao P, Xe R: Risk factors for bladder cancer: a case-control study in northeast China. Eur J Cancer Prev 1997;6:363–369.
37.
De Stefani E, Boffetta P, Ronco AL, Deneo-Pellegrini H, Acosta G, Mendilaharsu M: Dietary patterns and risk of bladder cancer: a factor analysis in Uruguay. Cancer Causes Control 2008;19:1243–1249.
38.
Vena JE, Graham S, Freudenheim J, Marshall J, Zielezny M, Swanson M, Sufrin G: Drinking water, fluid intake, and bladder cancer in western New York. Arch Environ Health 1993;48:191–198.
39.
Goebell PJ, Villanueva CM, Rettenmeier AW, Rubben H, Kogevinas M: Environmental exposure, chlorinated drinking water, and bladder cancer. World J Urol 2004;21:424–432.
40.
Ros MM, Bas Bueno-de-Mesquita HB, Buchner FL, et al: Fluid intake and the risk of urothelial cell carcinomas in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2011;128:2695–2708.
41.
Boehm K, Borrelli F, Ernst E, Habacher G, Hung SK, Milazzo S, Horneber M: Green tea (Camellia sinensis) for the prevention of cancer. Cochrane Database Syst Rev 2009;3: CD005004.
42.
Wakai K, Ohno Y, Obata K, Aoki K: Prognostic significance of selected lifestyle factors in urinary bladder cancer. Jpn J Cancer Res 1993;84:1223–1229.
43.
Demirel F, Cakan M, Yalcinkaya F, Topcuoglu M, Altug U: The association between personal habits and bladder cancer in Turkey. Int Urol Nephrol 2008;40:643–647.
44.
Zeegers MP, Kellen E, Buntinx F, van den Brandt PA: The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review. World J Urol 2004;21:392–401.
45.
Graham HN: Green tea composition, consumption, and polyphenol chemistry. Prev Med 1992;21:334–350.
46.
Khan N, Afaq F, Saleem M, Ahmad N, Mukhtar H: Targeting multiple signaling pathways by green tea polyphenol (–)-epigallocatechin-3-gallate. Cancer Res 2006;66:2500–2505.
47.
Anderson RF, Fisher LJ, Hara Y, Harris T, Mak WB, Melton LD, Packer JE: Green tea catechins partially protect DNA from (.)OH radical-induced strand breaks and base damage through fast chemical repair of DNA radicals. Carcinogenesis 2001;22:1189–1193.
48.
Nam S, Smith DM, Dou QP: Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 2001;276:13322–13330.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.